


FIG. 1








FIG. 3





FIG. 4

Quinacrine treatment 6 days [μM] Followup 3 weeks after discontinuation

0 0.8 0.6 0.4 0.2 0 0.2 0.4 0.6 0.8 0.2



PrP<sup>Sc</sup> formation in ScN2a cells treated with (+)- and (-)- Quinacrine




FIG. 5A

FIG. 5B

**Inventor(s):** Prusiner et al.  
**Title:** Cyclic Bis-Compounds Clearing  
 Malformed Proteins  
**Serial No.:** To Be Assigned  
**Filing Date:** Herewith (Nov. 25, 2003)  
**Attorney Docket:** UCAL-243




FIG. 6

Inventor(s): Prusiner et al.  
Title Cyclic Bis-Compounds Clearing  
Malformed Proteins  
Serial No.: To Be Assigned  
Filing Date: Herewith (Nov. 25, 2003)  
Attorney Docket: UCAL-243




FIG. 7A




FIG. 7B




FIG. 7C

**Inventor(s):** Prusiner et al.  
**Title** Cyclic Bis-Compounds Clearing  
 Malformed Proteins  
**Serial No.:** To Be Assigned  
**Filing Date:** Herewith (Nov. 25, 2003)  
**Attorney Docket:** UCAL-243




FIG. 8A




FIG. 8B




FIG. 8C



Inventor(s): Prusiner et al.  
Title Cyclic Bis-Compounds Clearing  
Malformed Proteins  
Serial No.: To Be Assigned  
Filing Date: Herewith (Nov. 25, 2003)  
Attorney Docket: UCAL-243




FIG. 9A




FIG. 9B